|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
As previously reported, MYC-expressing mice exhibited hepatoblastoma- and hepatocellular carcinoma-like tumors, which regressed when MYC expression was suppressed.
|
27197165 |
2016 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Pearson's correlation and Linear Regression analysis using the expression data from GSE55092 (HCC) and GSE4290 (GBM) demonstrated a converse relationship of MC-let-7a-1~let-7d and MYC only in HCC but not in GBM.
|
27409345 |
2016 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expression of the BCAT1 and MYC proteins in 122 HCC tissues was determined with an immunohistochemical analysis.
|
27246112 |
2016 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Multiple sets of genes and molecular biological processes involved during HCC development were identified from this integrative analysis: (i) Loss of liver cellular features due to the reduced HNF4A & PPAR signaling in the early stages of HCC, (ii) activated inflammatory and stress signals in the cirrhosis stages and (iii) highly activated cellular proliferation with the activated E2F-MYC oncogenic signaling with the gain of embryonic liver stem cell-like features in the advanced stage tumors.
|
27194100 |
2016 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Compared with results in untreated animals with MYC-induced hepatocellular carcinoma, administration of the GLS-specific inhibitor bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) prolonged survival without any apparent toxicities.
|
25915584 |
2015 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We predicted that CDH1, ECHS1, ACAA1, MT2A, and MYC might be target genes for diagnosing HCC.
|
25768320 |
2015 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A combined immunohistochemical and tissue microarray analysis of 81 human HCC tissues revealed that CYLD expression is negatively correlated with expression of proliferation markers Ki-67 and c-MYC.
|
24104553 |
2014 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Real-time reverse-transcription polymerase chain reaction (RT-PCR) and northern blot analysis demonstrated reduced expression of the primary, precursor, and mature miR-122 in c-MYC-induced HCCs compared to the benign livers, indicating transcriptional suppression of miR-122 upon MYC overexpression.
|
24038073 |
2014 |
|
Liver carcinoma
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells.
|
25108398 |
2014 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The MYC oncogene is overexpressed in hepatocellular carcinoma (HCC) and has been associated with widespread microRNA (miRNA) repression; however, the underlying mechanisms are largely unknown.
|
24002871 |
2014 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma.
|
25128497 |
2014 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated this triad for the first time in hepatocellular carcinoma (HCC), where miR-17-5p showed a significant down-regulation in 23 non-metastatic HCC biopsies compared to 10 healthy tissues; however, E2F-1 and c-MYC transcripts were markedly elevated.
|
23583198 |
2013 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Multivariate analysis verified that the AFP and c-myc status (amplified vs. not amplified) were significant prognostic factors for overall patients survival. c-myc gene amplification is significantly correlated with disease-free survival and overall survival in patients with hepatocellular carcinoma after surgical resection and this model identifies patients with risk of early relapse (≤12 months).
|
23874541 |
2013 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Amplification of broad regions of 8q is one of the most frequent genetic alterations in hepatocellular carcinoma (HCC), suggesting the existence of oncogenes in addition to MYC at 8q24.21.
|
22262416 |
2012 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expression of CIP2A and c-MYC was examined by immunohistochemistry in 136 HCC specimens.
|
22847158 |
2012 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Depletion of ARK5 prolongs survival in MYC-driven mouse models of hepatocellular carcinoma, demonstrating that targeting cellular energy homeostasis is a valid therapeutic strategy to eliminate tumour cells that express deregulated MYC.
|
22460906 |
2012 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Compelling evidence demonstrates that DLC1, a potent TSG on 8p, and MYC oncogene on 8q play a critical role in the pathogenesis of human HCC.
|
22580498 |
2012 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Treatment of the human hepatoma cell line HepG2 with hepatic growth factor (Hgf) caused c-Myc protein induction and transcriptional up-regulation of candidate genes, albeit at different levels when individual genes were compared.
|
22653869 |
2012 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
DKC1 mRNA was significantly overexpressed in HCC tissues and showed a significant correlation with MKI67 and MYC mRNA but a weak correlation with TERT mRNA.
|
22912812 |
2012 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
RGD |
Mechanistic study on liver tumor promoting effects of flutamide in rats.
|
22076107 |
2012 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The inhibition of HMG-CoA reductase may be a useful target for the treatment of MYC-associated HCC as well as other tumors.
|
21262914 |
2011 |
|
Liver carcinoma
|
0.600 |
Therapeutic
|
disease |
RGD |
Antioxidant N-acetyl-L-cysteine (NAC) supplementation reduces reactive oxygen species (ROS)-mediated hepatocellular tumor promotion of indole-3-carbinol (I3C) in rats.
|
22129741 |
2011 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The transcriptomic analysis of CSN5 knockdown signature showed that the anti-proliferative effect was driven by a common subset of molecular alterations including down-regulation of cyclin-dependent kinase 6 (CDK6) and integrin β1 (ITGB1), which were functionally interconnected with key oncogenic regulators MYC and TGFβ1 involved in the control of proliferation, apoptotic cell death and HCC progression.
|
21499307 |
2011 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we sought to test whether loss of RB function would affect cancer development in a mouse model of c-MYC-induced hepatocellular carcinoma (HCC), a deadly cancer type in which RB is frequently inactivated and c-MYC often activated.
|
21573126 |
2011 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The molecular profile of the HCV-associated HCC confirmed central roles for MYC and TGFbeta1 in liver tumor development.
|
20380719 |
2010 |